Fulcrum Therapeutics, Inc.·4

Jan 28, 4:15 PM ET

Oltmans Curtis Gale 4

4 · Fulcrum Therapeutics, Inc. · Filed Jan 28, 2025

Insider Transaction Report

Form 4
Period: 2025-01-24
Oltmans Curtis Gale
Chief Legal Officer
Transactions
  • Award

    Stock Option (right to buy)

    2025-01-24+225,000225,000 total
    Exercise: $4.16Exp: 2035-01-24Common Stock (225,000 underlying)
Footnotes (1)
  • [F1]This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4